Capital Advisors Inc. OK trimmed its holdings in Abbott Laboratories (NYSE:ABT) by 2.1% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 27,646 shares of the healthcare product maker’s stock after selling 600 shares during the quarter. Capital Advisors Inc. OK’s holdings in Abbott Laboratories were worth $2,813,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. PNC Financial Services Group Inc. boosted its holdings in shares of Abbott Laboratories by 0.3% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,743,386 shares of the healthcare product maker’s stock worth $433,687,000 after buying an additional 12,475 shares during the period. WFA of San Diego LLC bought a new stake in shares of Abbott Laboratories during the 2nd quarter worth $1,088,000. Handelsbanken Fonder AB boosted its holdings in shares of Abbott Laboratories by 32.9% during the 2nd quarter. Handelsbanken Fonder AB now owns 1,467,408 shares of the healthcare product maker’s stock worth $134,165,000 after buying an additional 362,969 shares during the period. Nuveen Asset Management LLC boosted its holdings in shares of Abbott Laboratories by 3.7% during the 2nd quarter. Nuveen Asset Management LLC now owns 10,100,593 shares of the healthcare product maker’s stock worth $923,496,000 after buying an additional 359,477 shares during the period. Finally, Stephens Inc. AR boosted its holdings in shares of Abbott Laboratories by 5.6% during the 2nd quarter. Stephens Inc. AR now owns 242,733 shares of the healthcare product maker’s stock worth $22,193,000 after buying an additional 12,765 shares during the period. 73.09% of the stock is owned by institutional investors.
Several analysts recently issued reports on the stock. Stifel Nicolaus upped their price objective on shares of Abbott Laboratories from $108.00 to $115.00 and gave the stock a “buy” rating in a report on Thursday, August 27th. BTIG Research reissued a “hold” rating on shares of Abbott Laboratories in a report on Thursday, August 27th. Goldman Sachs Group set a $94.00 price target on shares of Abbott Laboratories and gave the company a “sell” rating in a report on Wednesday, September 2nd. Wolfe Research began coverage on shares of Abbott Laboratories in a report on Friday, September 11th. They issued an “outperform” rating and a $124.00 price target for the company. Finally, Credit Suisse Group increased their price target on shares of Abbott Laboratories from $109.00 to $136.00 and gave the company an “outperform” rating in a report on Monday, August 31st. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $111.19.
Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.15. The business had revenue of $7.33 billion during the quarter, compared to analysts’ expectations of $6.85 billion. Abbott Laboratories had a net margin of 9.89% and a return on equity of 17.34%. The firm’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same quarter last year, the company posted $0.82 EPS. On average, research analysts predict that Abbott Laboratories will post 3.27 EPS for the current fiscal year.
In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 42,479 shares of the stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $111.86, for a total transaction of $4,751,700.94. Following the sale, the executive vice president now owns 144,912 shares of the company’s stock, valued at approximately $16,209,856.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Randel William Woodgrift sold 2,500 shares of the stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $105.28, for a total transaction of $263,200.00. Following the sale, the senior vice president now directly owns 46,267 shares in the company, valued at approximately $4,870,989.76. The disclosure for this sale can be found here. In the last three months, insiders have sold 81,121 shares of company stock worth $8,636,628. Insiders own 1.70% of the company’s stock.
Abbott Laboratories Company Profile
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.
Further Reading: What is range trading?
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.